BioLine Rx Analyst Ratings
Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
BioLine Rx Analyst Ratings
BioLine Rx Analyst Ratings
Positive Outlook for Bioline RX With Promising Phase 2 Trial Results and New Product Launch: A Buy Rating
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Bioline RX Ltd Sponsored ADR (BLRX) and Arrowhead Pharmaceuticals (ARWR)
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
BioLine Rx Analyst Ratings
Bioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future Growth
Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), Biogen (BIIB) and Walgreens Boots Alliance (WBA)
HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21
BioLine Rx Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $19 Price Target
BioLine Rx Analyst Ratings
Bioline RX Ltd Sponsored ADR (BLRX) Receives a Buy From H.C. Wainwright
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Soleno Therapeutics (SLNO) and Bioline RX Ltd Sponsored ADR (BLRX)
Oppenheimer Reiterates Outperform on BioLine Rx, Maintains $4 Price Target
H.C. Wainwright Sticks to Its Buy Rating for Bioline RX Ltd Sponsored ADR (BLRX)
H.C. Wainwright Remains a Buy on Bioline RX Ltd Sponsored ADR (BLRX)
Bioline RX Ltd Sponsored ADR (BLRX) Receives a Buy From H.C. Wainwright
No Data